Segment Reporting

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Segment Reporting

Note 13 – Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. The financial results of the Company’s operations are managed and reported to the Chief Executive Officer who is considered the Company’s chief operating decision maker (CODM), on a consolidated basis.

The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.

As a single reportable segment entity, the Company’s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Segment expenses
Salaries and Benefits	$	2,857,617		$	4,124,151		$	6,686,838		$	8,307,421
Professional fees		1,278,581			1,688,412			2,405,627			2,765,678
General administrative expenses		387,897			378,905			732,251			743,567
Clinical development expenses		2,017,145			1,004,848			2,455,049			2,846,909
Other development expenses		1,082,111			1,487,988			4,449,344			4,118,356
Total operating and segment expenses	$	7,623,351		$	8,684,304		$	16,729,109		$	18,781,931
Interest income		333,624			675,209			711,473			1,344,104
Interest expense		(2,144,481	)		(1,187,971	)		(3,075,359	)		(2,362,716	)
Benefit from income taxes		-			869,169			1,169,820			869,169
Segment and consolidated net loss	$	(9,434,208	)	$	(8,327,897	)	$	(17,923,175	)	$	(18,931,374	)